rawfin.tv
Olema Oncology, Bayer Partner on Prostate Cancer Drug Trial
Top StoriesstocksAI Generated

Olema Oncology, Bayer Partner on Prostate Cancer Drug Trial

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Olema Oncology has announced a clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136. The trial will assess OP-3136 in combination with Bayer's NUBEQA® for metastatic castration-resistant prostate cancer.

OLMABAYNBiotechClinical TrialsPharmaceuticalsProstate Cancer

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks